

patients regarding the documents was not part of the intervention in any group.

Three months after the intervention, charts were audited for presence of advance directives. No charts in any group contained advance directives. We interpreted this to mean that a simple distribution of information without discussion by a health care worker, even when accompanied by literature written in lay terms, has no effect on increasing the number of advance directives presented to the physician or office for the medical record. Like Richter et al, we are unsure if patient education elicited any positive effects such as prompting discussion among patients and significant others or other positive effects.

These studies, however, do underline the importance of personal discussion in the facilitation of behavioral changes, including the completion of advance directives.

Mary Thoesen Coleman, MD, PhD  
Randy Jerneckic  
Department of Family Medicine  
The Ohio State University  
Columbus

1. Richter PK, Langel S, Fawcett SB, Paine-Andrews A, Biehler L, Manning R. Promoting the use of advance directives: an empirical study. *Arch Fam Med.* 1995;4:609-615.

---

In reply

Following passage of the Patient Self-Determination Act,<sup>1</sup> hospitals and other health care entities created a plethora of forms and informational materials. Yet it is not at all clear that information alone increases completion and filing of advance directives among the general public. Coleman and Jerneckic's experience is likely the rule among those who have sought to increase the use of advance directives.

Pearlman<sup>2</sup> suggested that we "identify the optimal circumstances for advance care planning: where and when (inpatient, outpatient, health promotion screening visits), who should be involved, and how often advance directives should be discussed and reviewed." For some ethnic groups, information or discussions about end-of-life decision making may be anathema. Carrese and Rhodes<sup>3</sup> found that discussing negative information conflicts with traditional Navajo values and may be viewed as potentially harmful by Navajo patients. Likewise, Blackhall and colleagues<sup>4</sup> found that Korean American patients preferred that their families handle end-of-life treatment decisions.

Two studies have demonstrated that mailed forms and information increase use of advance directives by older adults.<sup>5,6</sup> Older adults daily face the passing of family, friends, and even public figures that they have known and loved. Natural consequences, such as reduced anxiety for spouses or relatives, may reinforce decisions to adopt advance directives. It may be that for certain populations, who have already had multiple exposures to end-of-life decision making, mailed or hand-delivered materials are sufficient prompts for increasing use.

To summarize, there are likely a vast number of conditions that would increase the use of advance directives, or the use of other procedures to enhance patient autonomy in end-of-life decision making. These conditions will likely vary according to race, ethnicity, age, and health status of groups within the general population. The challenge lies in identifying those conditions and identifying types of advance directives that mesh with individual belief systems.

We could take one more step toward true patient autonomy by providing resources for grassroots development of advance directives. Perhaps community-based mini-grants to religious, health advocacy, and ethnic groups would facilitate the development of culturally appropriate procedures for increasing patient autonomy. Grantmakers could encourage collaboration with health and legal professionals and provide technical assistance in adapting procedures for advance directives to diverse groups. Particularly effective procedures might then be disseminated at the state or national level. Such strategies may enhance opportunities for all to engage in meaningful end-of-life decision making.

Kimber P. Richter, MA  
Stephen B. Fawcett, PhD  
Adrienne Paine-Andrews, PhD  
University of Kansas  
Lawrence  
Sondra Langel  
Kansas Health Ethics  
Wichita  
Lucia Biehler, RN  
Wichita Medical Practice Association  
Robert Manning, MD  
University of Kansas School of Medicine  
Wichita

1. Omnibus Reconciliation Act of 1990. Pub L. No. 101-508, §4206, 4751.
2. Pearlman RA. Are we asking the right questions? *Hastings Center Rep.* 1994; 24(suppl):S24-S27.
3. Carrese JA, Rhodes LA. Western bioethics on the Navajo Reservation: benefit or harm? *JAMA.* 1995;274:826-829.
4. Blackhall IJ, Murphy ST, Frank G, Michel V, Azen S. Ethnicity and attitudes toward patient autonomy. *JAMA.* 1995;274:820-825.
5. High DM. Advance directives and the elderly: a study of intervention strategies to increase use. *Gerontologist.* 1993;33:342-349.
6. Rubin S, Strull WM, Fialkow MF, Weiss SJ, Lo B. Increasing the completion of the durable power of attorney for health care: a randomized, controlled trial. *JAMA.* 1994;271:209-212.

---

## Addiction to Benzodiazepines— How Common?

In his article,<sup>1</sup> Dr Piper states "the literature provides no support for the notion that benzodiazepines are often used recklessly, in escalating dosage, or inappropriately" and "the belief that benzodiazepines are frequently consumed despite harmful medical effects and adverse social consequences, as required by the definition of addiction used . . . is not supported by the available literature." With regard to at least 1 large group of patients frequently seen by family physicians, these statements are untrue.

It has been shown that many patients with chronic pain conditions receive benzodiazepines despite evidence that they provide little benefit in these patients and may, in fact, be detrimental.<sup>2-4</sup> These medications may impair functioning, the improvement of which is the usual goal in the management of chronic pain, and may even exacerbate pain by lowering the pain threshold. In my own experience with the patients with chronic pain whom I treat, who are functioning poorly and taking benzodiazepines, I have found that many refuse to consider withdrawing these medications. This is despite the fact that many of these patients state that they are seeking any relief they can from their pain and would even be willing to consider painful invasive procedures if they might help alleviate their suffering. Yet the one thing many will not consider is discontinuing the benzodiazepine.

Benzodiazepines are useful medications for many patients. However, the belief that there is little misuse of these medications is contradicted by the literature.

Steven A. King, MD, MS  
Director, Division of Pain Medicine  
Temple University School of Medicine  
Philadelphia, Pa

1. Piper A. Addiction to benzodiazepines—how common? *Arch Fam Med.* 1995;4:964-970.
2. King SA, Strain JJ. Benzodiazepine use by chronic pain patients. *Clin J Pain.* 1990;6:143-147.
3. King SA, Strain JJ. Benzodiazepines and chronic pain. *Pain.* 1990;41:3-4.
4. Dellemijn PLI, Fields HL. Do benzodiazepines have a role in chronic pain management? *Pain.* 1994;57:137-152.

In a recent article<sup>1</sup> on addiction to benzodiazepines, the author reported the absence of data linking this drug class to “significant tissue or organ morbidity” and cited a 1983 article as his first reference.

Although earlier literature may have suggested that benzodiazepines are relatively safe drugs (as compared with the barbiturates), there is now a body of observational research suggesting that safety is an important problem for subgroups such as elderly patients. For example, an association between benzodiazepines and adverse events such as falls, hip fracture, cognitive impairment, and motor vehicle crash has been demonstrated in elderly patients.<sup>2-10</sup>

I agree with the author's comment that it may be difficult to weigh the benefits and risks of drug therapy and that such analyses involve value judgments. However, to promote informed decision making, clinicians should be aware that certain subgroups of patients, such as elderly users of benzodiazepines, may be exposed to an increased risk of injury.

Roland Grad, MD  
McGill University  
Montreal, Quebec

1. Piper A Jr. Addiction to benzodiazepines—how common? *Arch Fam Med.* 1995;4:964-970.
2. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. *N Engl J Med.* 1988;319:1701-1707.
3. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. *Arch Intern Med.* 1988;148:2441-2444.
4. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. *N Engl J Med.* 1987;316:363-369.
5. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short half-life and the risk of hip fracture. *JAMA.* 1989;262:3303-3307.
6. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM. Risk factors for hip fracture in white women. *N Engl J Med.* 1995;332:767-773.
7. Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. *Clin Pharmacol Ther.* 1977;21:355-361.
8. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse reactions associated with global cognitive impairment in elderly persons. *Ann Intern Med.* 1987;107:169-173.
9. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. *Am J Epidemiol.* 1992;136:873-883.
10. Herings RMC, Stricker BHCh, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. *Arch Intern Med.* 1995;155:1801-1807.

#### Clinical Pearl

Stearic acid, a saturated fatty acid, was associated with a 37% increase in the risk of stroke, and alpha linolenic acid, an unsaturated fatty acid, was associated with a 28% decrease in the risk of stroke. (*Stroke.* 1995;26:778-782.)